Asuragen's test detects cystic fibrosis gene variants

By The Science Advisory Board staff writers

November 8, 2021 -- Asuragen, a Bio-Techne brand, has launched a new test kit to detect pathogenic variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

The AmplideX PCR/CE CFTR Kit, which is intended for research use only, delivers results in less than five hours. It is designed to detect approximately 93% of CFTR pathogenic variants observed in the U.S. population. It can also identify a broad range of variant types, including copy number variants; single tandem repeats; and single nucleotide polymorphisms, insertions, and deletions. The kit can resolve variant zygosity.

Furthermore, it is optimized for use on polymerase chain reaction (PCR) and capillary electrophoresis laboratory equipment, and the kit can be combined with Asuragen's AmplideX PCR/CE FMR1 Kit and the SMN1/2 Plus Kit to provide the same-platform assay for this trio of the most prevalent and commonly analyzed carrier genes.

Bio-Techne launches iPSC expansion medium
Bio-Techne has unveiled ExCellerate iPSC Expansion Medium, a new medium to support the expansion and maintenance of induced pluripotent stem cells (iPSCs)...
Bio-Techne reports organic revenue growth for Q4
Bio-Techne reported an organic revenue increase of 39% for the fourth quarter of 2021.
Bio-Techne, Progen launch Simple Plex AAV2 immunoassay
Bio-Techne and Progen have launched the Simple Plex adeno-associated virus 2 (AAV2) viral titer assay for AAV2 total capsid quantification.
Bio-Techne launches multiplex spatial genomics assay
Bio-Techne has expanded its RNAscope in situ hybridization technology portfolio with the release of the new RNAscope HiPlex V2 assay for formalin-fixed,...
Bio-Techne opens new facility in Ireland
Bio-Techne has opened a new facility in Dublin as part of its efforts to support the life sciences industry in Europe.

Copyright © 2021 scienceboard.net


Conferences
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter